CareersInvestor RelationsPress RoomCOVID-19
Login

Welcome to Siemens Healthineers in the USA

Tools & Resources

News from Siemens Healthineers USA

Healthcare: available, affordable, and accepted – Best practices from three continents

 08/04/2022

Half the world’s population does not have access to healthcare. The barriers that stand between people and the care they need can be characterized as availability, affordability, and acceptability. Explore three best practices from three continents on how to overcome those challenges.

Transforming care delivery
Rethinking Cancer Care – A patient-centered best practice out of India

 07/18/2022

Explore how an international best practice improves access to cancer care for millions. HealthCare Global Enterprises (HCG), the largest cancer care provider in India, has developed an innovative hub-and-spoke model that increases availability and affordability for cancer patients.

Transforming care delivery
One-stop cancer care: Building a digitalized Oncology Center of Excellence

 07/01/2022

Explore important elements in building a successful Oncology Center of Excellence and how digital technologies support care coordination along the cancer treatment pathway.

Digitalizing healthcare
What have we overlooked in cancer care?

 06/21/2022

Emotionally accompanying patients along the cancer pathway can have a positive effect on patient experience.

Improving patient experience
MAGNETOM Free.Max: Powerful images for powerful people

 04/26/2022

With its 80 cm bore, MAGNETOM Free.Max makes MRI accessible for people with large body sizes.

Contact Us

Siemens Medical Solutions USA, Inc.

40 Liberty Boulevard
Malvern, PA 19355
United States of America

1The Dosimetry Research Tool shown in the image is an Investigational Device. Limited by Federal (or United States) law to investigational use. This device is exclusively for clinical investigations. This Investigational Device does not fulfill all the essential requirements according to the European Medical Device Directive (93/42/EEC) and its national implementations. It is not commercially available in the European Union, or other countries worldwide.